Catalent Biologics' Executive to Discuss Manufacturing Scale-up During a Pandemic
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 - 29, 2020.
SOMERSET, N.J., July 22, 2020 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 – 29, 2020.
On Tuesday, July 28 at 4:10 p.m. EDT, during his presentation titled, "How COVID-19 is Bending the Curve on Vaccine Development and Manufacturing Norms," Mr. Riley will discuss the challenges associated with scaling up manufacturing during the COVID-19 pandemic, including the need to condense vaccine development and clinical trial timelines, and establishing a global supply network that is capable of potentially delivering billions of doses worldwide. Using specific examples, he will explore how partnerships are enabling pharmaceutical companies of all sizes to meet unparalleled timelines in bringing treatments to patients as quickly as possible.
Immediately following his presentation, at 4:30 p.m. EDT, Mr. Riley will then join the "Manufacturing Drugs and Vaccines" panel session, moderated by Craig Laferrière, Head of Vaccine Development, Novateur Ventures Inc., which includes panelists from AstraZeneca and Translate Bio. The panelists will discuss the risks and challenges associated with pandemic drug manufacture and debate the extent to which vials that store vaccines could become a constraint, as well as the requirements that are needed in delivery systems and cold chain logistics.
Mr. Riley has worked at Catalent for 15 years, and held several leadership positions in that time. In his current role, he has overall responsibility for the strategy and management of Catalent's biologics business in North America, and has guided it through the recent COVID-19 pandemic, simultaneously navigating the challenges of continued operations, alongside the rapid preparation to supply of multiple customers' vaccine and treatment programs. Prior to joining Catalent, Mr. Riley worked as a management consultant for Marakon Associates, providing strategic advice to companies across multiple industries. He holds a bachelor's degree from Duke University, in Durham, North Carolina, and an MBA from The Wharton School at the University of Pennsylvania.
The event's presentations and panel discussions will be available to view on-demand through the conference platform. For more information about the event, please visit biologics.catalent.com/events/disease-prevention-control-summit-america-2020/
About Catalent Biologics
Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx® cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com
About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™
SOURCE Catalent
Share this article